Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

NRx Pharmaceuticals, Inc. (NRXPW)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.1480+0.0017 (+1.16%)
At close: 04:00PM EDT
Advertisement

NRx Pharmaceuticals, Inc.

1201 Orange Street
Suite 600
Wilmington, DE 19801
United States
484 254 6134
https://www.nrxpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Robert Besthof M.I.M.Interim CEO, Head of Operations & Chief Commercial Officer264kN/A1967
Dr. Jonathan C. Javitt M.D., M.P.H.Co-Founder, Chief Scientist & Director377.29kN/A1957
Ms. Alessandra Daigneault Esq.Chief Corp. Officer, Gen. Counsel & Corp. Sec.634.96kN/A1965
Mr. Randolph Guggenheimer IIIChief Bus. Officer215.77kN/AN/A
Prof. Daniel C. JavittCo-Founder & Chairman of Scientific Advisory BoardN/AN/AN/A
Mr. Ira S. StrassbergCFO & TreasurerN/AN/A1967
Ms. Molly CoganSr. Director of Global CommunicationsN/AN/AN/A
Dr. Philip T. LavinChief MethodologistN/AN/A1947
Dr. Dennis K. McBride Ph.D.Chief Strategy Officer & Sr. ScientistN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Corporate Governance

NRx Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement